Implanted Nerve Stimulator for Sleep Apnea: New Trial Shows Safety and Efficacy

What Is Proximal Hypoglossal Nerve Stimulation for Sleep Apnea?

Obstructive sleep apnea (OSA) occurs when the muscles of the upper airway relax during sleep, causing repeated episodes of airway collapse, oxygen desaturation, and sleep fragmentation. The hypoglossal nerve controls the muscles of the tongue, and selectively stimulating certain fibers can push the tongue forward and stiffen the airway, preventing collapse. Proximal hypoglossal nerve stimulation (pHGNS) targets nerve sectors higher up the neural pathway than earlier distal stimulation systems, aiming to recruit a broader set of airway-dilating muscles with a single implant.

The device consists of a small pulse generator implanted under the skin, similar in size to a cardiac pacemaker, connected to a stimulation lead placed around the hypoglossal nerve. A sensor detects breathing patterns and triggers stimulation synchronized with inspiration. Patients activate the device at bedtime using a handheld remote and turn it off upon waking.

How Effective Is the Implant Compared With CPAP?

Continuous positive airway pressure (CPAP) remains the first-line therapy for moderate-to-severe OSA and is highly effective when used consistently. However, adherence is a persistent problem: research consistently shows that a substantial proportion of patients stop using CPAP within the first year due to mask discomfort, claustrophobia, dry airways, or disrupted sleep from the device itself. For these patients, untreated OSA carries elevated risks of hypertension, stroke, cardiovascular disease, and daytime impairment.

Hypoglossal nerve stimulation has emerged over the past decade as a second-line option for carefully selected patients. The new randomized controlled trial of the proximal approach reports meaningful reductions in nightly apnea events and favorable safety outcomes, with adverse events largely limited to procedure-related soreness and transient tongue weakness. Unlike CPAP, the device works silently and invisibly once implanted, which has been linked to higher long-term adherence in earlier studies of distal systems.

Who Is a Candidate for This Therapy?

Selection criteria for hypoglossal nerve stimulation have historically included moderate-to-severe OSA defined by apnea-hypopnea index thresholds, documented CPAP failure or intolerance, and absence of complete concentric collapse at the palate on sleep endoscopy. Body mass index limits have also applied because obesity can reduce the effectiveness of airway stimulation. The proximal approach may broaden the anatomical profiles that respond to therapy, though confirmatory data are still emerging.

Patients considering the implant should be evaluated by a multidisciplinary team including sleep medicine specialists and otolaryngologists experienced with the device. Shared decision-making should cover surgical risks, battery replacement timelines, MRI compatibility, and realistic expectations — the therapy typically reduces but does not eliminate apnea events, and lifestyle factors such as weight management and alcohol moderation remain important.